

30 April 2018

ASX Announcement
Strong growth and development of BodyTel continues

Lifespot Health Ltd ("Company") are pleased to provide the attached Appendix 4C for the March 2018 quarter and an update on the progress of business development of the BodyTel platform.

Key financial and operational details for the quarter are as follows;

- \$166k in Cash Receipts from customers for the March quarter representing strong revenue from LSH's key client BBRUAN
- Ongoing optimisation of operating costs during quarter 1
- Advanced Body-Tel architecture ready for patient self-management with 8 sensors integrated
- Accelerated development of Seng-Vital digital cannabis vaporiser
- Strong balance sheet with cash of \$4,516,000 as at 31st March 2018

Body-Tel is an integrated digital diagnostic and monitoring system that combines enhanced sensor technology with self-learning algorithms, allowing patients and healthcare professionals to efficiently monitor chronic diseases and critical conditions on their personal and professional digital devices including Smartphone, iPad / Tablets and desktop.

Located in Germany the Company's team of medically focussed digital developers have a rigorous quality management system (QMS) that is ISO 13485 and IEC/EN 62304 certified. These certifications and the Company's capability in digital health development have led to the establishment of a strong project pipeline in 2018 with B. Braun, Beurer and five other diagnostic and device manufactures and marketers in Europe.

The Company's current business development focus is to drive to commercialisation of over ten development projects during 2018 and 2019 that will lead to ongoing licencing and service contracts of the Body-Tel platform.

The Company has also invested in a 50/50 Joint Venture with Seng-Tel, a digitally integrated Cannabis Vaporiser. The finger print activated vaporisers embedment in the medically certified software infrastructure of BodyTel allows both patients and authorised physicians to retrieve and evaluate the readings and data collected by the vaporiser, controlling the application history "from the outside" and supporting safety and compliance in the new therapeutic area of cannabinoids. Seng Vital, together with a leading device manufacturer, will have developed the "reference standard" of a vaporizer for medical cannabis delivery to the market by the end of July 2018.



For further information:

Mr Justyn Stedwell

Company Secretary

(03) 9191 0135

About Lifespot Health Ltd.

Lifespot Health an ISO 13485 certified company, operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money.

Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients and healthcare professionals to efficiently monitor chronic diseases and critical conditions on their personal and professional digital devices including Smartphone, iPad / Tablets and desktop.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

LIFESPOT HEALTH LTD

ABN

90 611 845 820

Quarter ended ("current quarter")

31 MARCH 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	166	166
1.2 Payments for		
(a) research and development	(611)	(611)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs		
(f) administration and corporate costs	(191)	(191)
1.3 Dividends received (see note 3)		
1.4 Interest received	24	24
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(612)	(612)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	-	-

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	4,516	4,516
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(612)	(612)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		
4.4 Net cash from / (used in) financing activities (item 3.10 above)		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	3,904	3,904

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	404	316
5.2	Call deposits	3,500	4,200
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,904	4,516

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

76

0

Directors and consulting fees

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter
\$A'000**

8. Financing facilities available

Add notes as necessary for an understanding of the position

- 8.1 Loan facilities
- 8.2 Credit standby arrangements
- 8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9. Estimated cash outflows for next quarter

\$A'000

9.1	Research and development	600
9.2	Product manufacturing and operating costs	
9.3	Advertising and marketing	
9.4	Leased assets	
9.5	Staff costs	
9.6	Administration and corporate costs	120
9.7	Other (provide details if material)	
9.8	Total estimated cash outflows	720

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)

Acquisitions

Disposals

10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Company secretary)

Date: 30/4/18

Print name: Justyn Stedwell
On behalf of the Board of Directors

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.